Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Management of refractory Mycoplasma pneumoniae pneumonia: utility of measuring serum lactate dehydrogenase level.

Inamura N, Miyashita N, Hasegawa S, Kato A, Fukuda Y, Saitoh A, Kondo E, Teranishi H, Wakabayashi T, Akaike H, Tanaka T, Ogita S, Nakano T, Terada K, Ouchi K.

J Infect Chemother. 2014 Apr;20(4):270-3. doi: 10.1016/j.jiac.2014.01.001. Epub 2014 Jan 31.

PMID:
24486173
2.

Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults.

Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, Wakabayashi T, Nakano T, Ouchi K, Okimoto N.

J Infect Chemother. 2015 Mar;21(3):153-60. doi: 10.1016/j.jiac.2014.10.008. Epub 2014 Dec 19.

PMID:
25533771
3.

Lactate Dehydrogenase as a Biomarker for Prediction of Refractory Mycoplasma pneumoniae Pneumonia in Children.

Lu A, Wang C, Zhang X, Wang L, Qian L.

Respir Care. 2015 Oct;60(10):1469-75. doi: 10.4187/respcare.03920. Epub 2015 Jun 9.

4.

Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia.

Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, Kaneko T, Tsukano S, Taguchi T, Uchiyama M.

J Infect Chemother. 2011 Dec;17(6):803-6. doi: 10.1007/s10156-011-0265-7. Epub 2011 Jun 17.

PMID:
21681500
5.

Utility of serum ferritin and lactate dehydrogenase as surrogate markers for steroid therapy for Mycoplasma pneumoniae pneumonia.

Kawamata R, Yokoyama K, Sato M, Goto M, Nozaki Y, Takagi T, Kumagai H, Yamagata T.

J Infect Chemother. 2015 Nov;21(11):783-9. doi: 10.1016/j.jiac.2015.07.009. Epub 2015 Aug 19.

PMID:
26298038
6.
7.

Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.

Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, Teranishi H, Inoue M, Wakabayashi T, Akaike H, Ogita S, Kawasaki K, Terada K, Kishi F, Ouchi K.

Respirology. 2012 Feb;17(2):354-62. doi: 10.1111/j.1440-1843.2011.02102.x.

PMID:
22077195
8.

Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children.

Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T.

J Infect. 2008 Sep;57(3):223-8. doi: 10.1016/j.jinf.2008.06.012. Epub 2008 Jul 25.

PMID:
18656264
9.

Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid.

Lu A, Wang L, Zhang X, Zhang M.

Pediatr Pulmonol. 2011 Nov;46(11):1093-7. doi: 10.1002/ppul.21481. Epub 2011 Jun 22.

PMID:
21698787
10.

Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.

Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, Saito A, Kondo E, Teranishi H, Ogita S, Tanaka T, Kawasaki K, Nakano T, Terada K, Ouchi K.

Antimicrob Agents Chemother. 2013 May;57(5):2252-8. doi: 10.1128/AAC.00048-13. Epub 2013 Mar 4.

11.

More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.

Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z.

Antimicrob Agents Chemother. 2014;58(2):1034-8. doi: 10.1128/AAC.01806-13. Epub 2013 Nov 25.

12.

Gene and cytokine profile analysis of macrolide-resistant Mycoplasma pneumoniae infection in Fukuoka, Japan.

Matsuda K, Narita M, Sera N, Maeda E, Yoshitomi H, Ohya H, Araki Y, Kakuma T, Fukuoh A, Matsumoto K.

BMC Infect Dis. 2013 Dec 16;13:591. doi: 10.1186/1471-2334-13-591.

13.

[The clinical characteristics, treatment and outcome of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].

Bao F, Qu JX, Liu ZJ, Qin XG, Cao B.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Oct;36(10):756-61. Chinese.

PMID:
24433804
14.

The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children.

Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z.

PLoS One. 2016 May 26;11(5):e0156465. doi: 10.1371/journal.pone.0156465. eCollection 2016.

15.

Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia.

Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, Okimoto N; Atypical Pathogen Study Group.

BMC Infect Dis. 2012 May 31;12:126. doi: 10.1186/1471-2334-12-126.

16.

Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China.

Ma Z, Zheng Y, Deng J, Ma X, Liu H.

Pediatr Pulmonol. 2014 Jul;49(7):695-700. doi: 10.1002/ppul.22851. Epub 2013 Jul 17.

PMID:
23861188
17.

Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children.

Lung DC, Yip EK, Lam DS, Que TL.

Pediatr Infect Dis J. 2013 Dec;32(12):1396-9. doi: 10.1097/INF.0b013e3182a25c71.

PMID:
23817339
18.

Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan.

Wu HM, Wong KS, Huang YC, Lai SH, Tsao KC, Lin YJ, Lin TY.

J Infect Chemother. 2013 Aug;19(4):782-6. doi: 10.1007/s10156-012-0523-3. Epub 2012 Nov 30.

PMID:
23196653
19.

Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.

Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K.

Clin Infect Dis. 2012 Dec;55(12):1642-9. doi: 10.1093/cid/cis784. Epub 2012 Sep 12.

PMID:
22972867
20.

Characteristics of Mycoplasma pneumoniae infection identified on culture in a pediatric clinic.

Katsushima Y, Katsushima F, Suzuki Y, Seto J, Mizuta K, Nishimura H, Matsuzaki Y.

Pediatr Int. 2015 Apr;57(2):247-52. doi: 10.1111/ped.12513. Epub 2014 Dec 11.

PMID:
25265270

Supplemental Content

Support Center